【摘要】 目的观察EPOCH方案治疗非霍奇金淋巴瘤的临床疗效和毒副反应。方法经病理确诊为非霍奇金淋巴瘤35例,采用EP-OCH方案化疗,VP-16 50 mg/m2,ADM 10 mg/m2或E-ADM 12 mg/m2,VCR 0.4 mg/m2,溶解于生理盐水500 mL持续静滴24 h,第1~4天;CTX 750 mg/m2,静脉推注,第6天;强地松60 mg/m2,口服,第1~6天,21 d为1周期。结果35例中CR/CRU 11例(31.4%),PR 17例(48.6%),总有效率80.0%,其中复治23例,CR/CRU 6例(26.1%),PR 11例(47.8%),总有效率73.9%。主要毒副反应为白细胞、血小板减少,其中Ⅲ~Ⅳ度发生率分别为34.2%(12/35)和42.9%(15/35),心房纤颤2.9%(1/35)。结论EPOCH方案是治疗非霍奇金淋巴瘤有效的治疗方案,耐受性较好,值得进一步研究。更多还原

【Abstract】 Objective To observe the effect and toxicity of EPOCH regimen for patients with non-Hodgkin’s lymphoma.Methods 35 patients with pathologically diagnosed non-Hodgkin’s lymphoma were treated by EPOCH regimen,in particular: VP-16 50 mg/m2,ADM 10 mg/m2 or E-ADM 12 mg/m2,VCR 0.4 mg/m2,dissolved in 500 mL saline sustained static drops 24 h on day 1 to 4;CTX 750 mg/m2,intravenous injection on day 6;oral prednisone 60 mg/m2 on day 1 to 6;21 days of a cycle.Results All the 35 patients were treated by EPOCH regimen.The response rate of the whole group was 80.0%,including CR/CRU 11 cases(31.4%),PR 17 cases(48.6%).The response rate of 23 patients with recurrence was 73.9%,including CR / CRU 6 cases(26.1%),PR 11 cases(47.8 %).Main toxicity was myelosuppression.The incidence of grade Ⅲ-Ⅳ neutropenia and thrombocytopenia respectively was 34.2%(12/35) and 42.9%(15/35);atrial fibrillation 2.9%(1/35).Conclusion EPOCH regimen is effective for patients with non-Hodgkin’s lymphoma and better tolerance.EPOCH regimen is warranted with clinical study.更多还原